Birnam Oak Advisors’s Astria Therapeutics ATXS Stock Holding History

Birnam Oak Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-689,735	Closed	-$9.03M	–	38
2025 Q4	$9.03M	Buy	+689,735	New	+$8.24M	2.02%	15

Birnam Oak Advisors's ATXS Position: Q1 2026 in Review

Birnam Oak Advisors sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 689,735 shares — an estimated $9.03M sold.

Birnam Oak Advisors first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $9.03M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Birnam Oak Advisors reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Birnam Oak Advisors sold 689,735 Astria Therapeutics shares in Q1 2026, an estimated $9.03M.
Birnam Oak Advisors first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
Birnam Oak Advisors's Astria Therapeutics position peaked at $9.03M in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Birnam Oak Advisors's 13F filing for Q1 2026, filed 12 May 2026.